Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
Yule A, Ng C, Recto A, Lockwood F, Dellschaft NS, Hoad CL, Zagoya C, Mainz JG, Major G, Barr HL, Gowland PA, Stewart I, Marciani L, Spiller RC, Smyth AR. Yule A, et al. Among authors: zagoya c. J Cyst Fibros. 2024 Sep;23(5):984-990. doi: 10.1016/j.jcf.2024.08.001. Epub 2024 Sep 5. J Cyst Fibros. 2024. PMID: 39242338 Free article.
Chronic rhinosinusitis in people with CF, a rapidly changing field.
Mainz JG, Duckstein F, Zagoya C, Koitschev A. Mainz JG, et al. Among authors: zagoya c. J Cyst Fibros. 2024 Mar;23(2):183-184. doi: 10.1016/j.jcf.2024.04.002. Epub 2024 Apr 10. J Cyst Fibros. 2024. PMID: 38604889 No abstract available.
Scoring Abdominal Symptoms in People with Cystic Fibrosis.
Tabori H, Barucha A, Zagoya C, Duckstein F, Dunay GA, Sadrieh P, Polte L, Mainz JG. Tabori H, et al. Among authors: zagoya c. J Clin Med. 2024 Mar 13;13(6):1650. doi: 10.3390/jcm13061650. J Clin Med. 2024. PMID: 38541878 Free PMC article. Review.
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Mainz JG, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L, Sadrieh P, Nährlich L, Eickmeier O, Van Dullemen S, Eschenhagen P, Schwarz C, Lüth S, Zagoya C, Graepler-Mainka U. Mainz JG, et al. Among authors: zagoya c. Front Pharmacol. 2023 Oct 25;14:1167407. doi: 10.3389/fphar.2023.1167407. eCollection 2023. Front Pharmacol. 2023. PMID: 38026920 Free PMC article.
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
Mainz JG, Lester K, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Zagoya C, Duckstein F, Barucha A, Davies JC, McNally P; RECOVER Study Group. Mainz JG, et al. Among authors: zagoya c. J Cyst Fibros. 2024 May;23(3):474-480. doi: 10.1016/j.jcf.2023.10.001. Epub 2023 Oct 7. J Cyst Fibros. 2024. PMID: 37806792
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C. Mainz JG, et al. Among authors: zagoya c. Front Pharmacol. 2023 May 3;14:1207356. doi: 10.3389/fphar.2023.1207356. eCollection 2023. Front Pharmacol. 2023. PMID: 37205908 Free PMC article.
Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage.
Erdmann N, Schilling T, Hentschel J, Lehmann T, von Bismarck P, Ankermann T, Duckstein F, Baier M, Zagoya C, Mainz JG. Erdmann N, et al. Among authors: zagoya c. Front Immunol. 2022 Nov 18;13:947359. doi: 10.3389/fimmu.2022.947359. eCollection 2022. Front Immunol. 2022. PMID: 36466839 Free PMC article.
17 results